Undifferentiated carcinoma of nasopharyngeal type (UCNT): A Swiss single-institutional experience during 1990-2005

Swiss Medical Weekly

Volumn 140, Issue 19-20, 2010, Pages 273-279

  Sidler, Daniel ^a   Winterhalder, Ralph ^b   Huber, Gerhard ^a   Haerle, Stephan K ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b LUZERNER KANTONSSPITAL   (Switzerland)

Author keywords

Nasopharyngeal carcinoma; Non endemic; Prognostic factors; Single institution; Survival

Indexed keywords

CISPLATIN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DELAYED DIAGNOSIS; DIAGNOSTIC PROCEDURE; FEMALE; HUMAN; MALE; MEDICAL RECORD REVIEW; NASOPHARYNX; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PHOTON THERAPY; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SWITZERLAND; UNDIFFERENTIATED CARCINOMA; WORLD HEALTH ORGANIZATION;

EID: 77952368486     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Beckmann G, and Flentje M. Present status of treatment in nasopharyngeal carcinoma? Strahlenther Onkol. 2003;179:283-291
2. Guigay J. Advances in nasopharyngeal carcinoma. Curr Opin Oncol. 2008;20:264-269
3. Parkin DM, Muir CS. Cancer Incidence in Five Continents. Comparability and quality of data. IARC Sci Publ. 1992;45-173.
4. Sham JS, Wei WI, Zong YS, et al. Detection of subclinical nasopharyngeal carcinoma by fibreoptic endoscopy and multiple biopsy. Lancet. 1990;335:371-374
5. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005;365:2041-2054
6. Chan AT, Teo PM, Huang DP. Pathogenesis and treatment of nasopharyngeal carcinoma. Semin Oncol. 2004;31:794-801.
7. Beer KT, Buhler SS, Mullis P, Laeng RH, and Greiner R. A microcystic adnexal carcinoma in the auditory canal 15 years after radiotherapy of a 12-year-old boy with nasopharynx carcinoma. Strahlenther Onkol. 2005;181:405-410
8. Hsu MM, Hong RL, Ting LL, Ko JY, Sheen TS, Lou PJ. Factors affecting the overall survival after salvage surgery in patients with recurrent nasopharyngeal carcinoma at the primary site: experience with 60 cases. Arch Otolaryngol Head Neck Surg. 2001;127:798-802.
9. Xia P, FU KK, Wong GW, et al. Comparison of treatment plans involving intensity-modulated radiotherpay for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2000;48:329-337
10. Kam MK, Chau RM, Suen J, et al. Intensity-modulated radiotherapy in nasopharyngeal carcinoma: Dosimetric advantage over conventional plans and feasibility of dose escalation. Int J Radiat Oncol Biol Phys. 2002;53:12-22.
11. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998;16:1310-1317
12. Chan AT, Leung SF, Ngan RK, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2005;97:536-539
13. Chi KH, Chang YC, Guo WY, et al. A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys. 2002;52: 1238-1244
14. Fountzilas G, Tolis C, Kalogera-Fountzila A, et al. Induction chemotherapy with cisplatin, epirubicin, and paclitaxel (CEP), followed by concomitant radiotherapy and weekly paclitaxel for the management of locally advanced nasopharyngeal carcinoma. A Hellenic Cooperative Oncology Group phase II study. Strahlenther Onkol. 2005;181:223-230
15. Gridelli C, Perrone F, Ianniello GP, et al. Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: a phase II study. Gruppo Oncologico Centro-Sud-Isole. J Clin Oncol. 1998;16:1414-1419
16. Jereczek-Fossa BA, Morra A, DeBraud F, et al. Hyperfractionated radiotherapy in locally advanced nasopharyngeal cancer. An analysis of 43 consecutive patients. Strahlenther Onkol. 2004;180:425-433
17. Lengyel E, Baricza K, Somogyi A, et al. Reirradiation of locally recurrent nasopharyngeal carcinoma. Strahlenther Onkol. 2003;179:298-305. (Pubitemid 36606020)
18. Kwong DL, Sham JS, Au GK, et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. J Clin Oncol. 2004;22:2643-2653
19. Buell P. Nasopharynx cancer in Chinese of California. Br J Cancer. 1965;19:459-470
20. Cannon T, Zanation AM, Lai V, and Weissler MC. Nasopharyngeal carcinoma in young patients: a systematic review of racial demographics. Laryngoscope. 2006;116:1021-1026 (Pubitemid 44318010)
21. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15:1765-1777
22. Kalogera-Fountzila A, Karanikolas D, Katodritis N, et al. Prognostic factors and significance of the revised 6th edition of the AJCC classification in patients with locally advanced nasopharyngeal carcinoma. Strahlenther Onkol. 2006;182:458-466 (Pubitemid 44214489)
23. I. Flemming, J. Cooper, and Henson. D Nasopharyngeal carcinoma, in AJCC Cancer staging Manual. Philadelphia: Lippincott-Raven, 1197.
24. Sobin L Nasopharyngeal Carcinoma, in TNM classification of malignant tumors. New York: Wiley-Liss, 1997.
25. Bailet JW, Mark RJ, Abemayor E, et al. Nasopharyngeal carcinoma: treatment results with primary radiation therapy. Laryngoscope. 1992;102:965-972
26. Dickson RI. Nasopharyngeal carcinoma: an evaluation of 209 patients. Laryngoscope. 1981;91:333-354 (Pubitemid 11155275)
27. Jiong L, Berrino F, Coebergh J. Eurocare working group. Variation in survival for adults with nasopharyngeal cancer in Europe, 1978-1989. Eur J Cancer. 1998;34:2162-2166
28. Venkitaraman R, Ramanan SG, Vasanthan A, et al. Results of combined modality treatment for nasopharyngeal cancer. J Cancer Res Ther. 2009;5:102-106
29. d'Espiney Amaro C, Montalvão P, Henriques P, et al. Nasopharyngeal carcinoma: our experience. Eur Arch Otorhinolaryngol. 2009;266(6):833-838
30. Khanfir A, Frikha M, Ghorbel A, et al. Prognostiv factors in metastatic nasopharyngeal carcinoma. Cancer Radiother. 2007;11(8):461-464 (Pubitemid 350236876)
31. Qi Y, Huang B, Yu L, et al. Prognostic value of Tiam1 and Rac1 overexpression in nasopharyngeal carcinoma. ORL J Otorhinolaryngol Relat Spec. 2009;71:163-171
32. King AD, Ahuja AT, Yeung DK, et al. Delayed complications of radiotherapy treatemnt of nasopharyngeal carcinoma: imaging findings. Clin Radiol. 2007;62:195-203. (Pubitemid 46217402)
33. Kong L, Lu J, Hu C, et al. The risk of second primary tumours in patients with nasopharyngeal carcinoma after definitive radiotherapy. Cancer. 2006;107(6):1287-1293 (Pubitemid 44452778)
34. Ng SH, Chan SC, Yen TC, et al. Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up. Eur J Nucl Med Mol Imag. 2009;36:538.
35. Yi JL, Gao L, Huang XD, et al. Nasopharyngeal carcinoma treated by radical radiotherapy alone: Ten-year experience of a single institution. Int J Radiat Oncol Biol Phys. 65:161-168
36. Hubert A, Jeannel D, Tuppin P, et al. Anthropology and epidemiology: a pluridisciplinary approach of environmental factors of nasopharyngeal carcinoma. In: Tursz T, Pagano JS, Ablashi DV, et al. (eds.), The Epstein-Barr virus associated diseases. 1993, pp775-788. Colloque INSERM, Vol 225, John Libbey Eurotext Ltd.
37. Kijima T, Kinukawa N, Gooding WE, et al. Association of Epstein-Barr virus with tumor cell proliferation: clinical implication in nasopharyngeal carcinoma. Int J Oncol. 2001;18:479-485